CNS5:Volunteer Assignments and Opportunities: Difference between revisions
No edit summary |
m due date |
||
| (28 intermediate revisions by 5 users not shown) | |||
| Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | ||
__TOC__ | |||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | ||
| Line 17: | Line 18: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
|CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) | | | ||
====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 42: | Line 44: | ||
|6/25/2023 | |6/25/2023 | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|Laveniya Satgunaseelan (LS) | |Laveniya Satgunaseelan (LS) | ||
| Line 50: | Line 52: | ||
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] | ||
|Disease | |Disease | ||
|Riley Lochner (trainee) | |Riley Lochner (trainee); | ||
Shashi Shetty (mentor) | |||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
| Line 61: | Line 64: | ||
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | ||
|Disease | |Disease | ||
| | |Jieying Wu | ||
| | |11/18/2025 | ||
| | |01/15/2026 | ||
|PENDING | |PENDING | ||
| | | | ||
| Line 108: | Line 111: | ||
|5/3/2024 | |5/3/2024 | ||
| | | | ||
|PENDING | |PENDING - email reminder 9/4/2025 | ||
| | | | ||
|LS | |LS | ||
| Line 116: | Line 119: | ||
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | ||
|Disease | |Disease | ||
|Laveniya Satgunaseelan | |Laveniya Satgunaseelan | ||
| | | | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|LS | |LS | ||
| Line 171: | Line 174: | ||
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | ||
|Disease | |Disease | ||
| | |Layla Zhu | ||
| | |<br />3/2/2026 | ||
| | | | ||
|PENDING | |PENDING | ||
| Line 182: | Line 185: | ||
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] | ||
|Disease | |Disease | ||
|Wahab Khan | |||
|2/8/2026 | |||
| | | | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 193: | Line 196: | ||
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] | ||
|Disease | |Disease | ||
|Wahab Khan | |||
|15/04/2025 | |||
| | | | ||
| | |COMPLETE | ||
| | |2/8/2026 (Feb 8) | ||
|LS | |LS | ||
| | | | ||
| Line 226: | Line 229: | ||
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] | ||
|Disease | |Disease | ||
|Milana.Djonovic (trainee), Laveniya/Madina | |||
|4/26/2026 | |||
|6/15/2026 | |||
|PENDING | |||
| | | | ||
| | |LS | ||
| | | | ||
| | | | ||
| Line 336: | Line 339: | ||
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] | ||
|Disease | |Disease | ||
|Laveniya Satgunaseelan | |||
|9/11/2024 | |||
| | | | ||
| | |COMPLETE | ||
| | |8/7/2025 | ||
| | |LS | ||
| | |LS | ||
| | |Used for testing 9/2024 somatic template | ||
|- | |- | ||
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] | ||
| Line 413: | Line 416: | ||
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] | ||
|Disease | |Disease | ||
| | |Laveniya Satgunaseelan | ||
| | |2/4/2026 | ||
| | |30/6/2026 | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 424: | Line 427: | ||
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] | ||
|Disease | |Disease | ||
| | |Laveniya Satgunaseelan | ||
| | |2/4/2026 | ||
| | |30/6/2026 | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 435: | Line 438: | ||
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] | ||
|Disease | |Disease | ||
| | |Laveniya Satgunaseelan | ||
| | |2/4/2026 | ||
| | |30/6/2026 | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 532: | Line 535: | ||
| | | | ||
|- | |- | ||
|CHAPTER 3 (CHOROID PLEXUS TUMOURS) | | | ||
====CHAPTER 3 (CHOROID PLEXUS TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 585: | Line 589: | ||
| | | | ||
|- | |- | ||
|CHAPTER 4 (EMBRYONAL TUMOURS) | | | ||
====CHAPTER 4 (EMBRYONAL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 607: | Line 612: | ||
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | ||
|Disease | |Disease | ||
|Lisa Lansdon, PhD (LGG trainee just finished) | |Lisa Lansdon, PhD (LGG trainee just finished); | ||
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | |||
|9/20/21 | |9/20/21 | ||
| | | | ||
| Line 629: | Line 635: | ||
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | ||
|Disease | |Disease | ||
|Hannah Wollenzien | |||
|1/11/2026 | |||
| | | | ||
|Pending | |||
| | | | ||
|MS | |||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | !'''Page Type''' | ||
!'''<span style="color:#0070C0">Author''' | !'''<span style="color:#0070C0">Author''' | ||
| Line 737: | Line 743: | ||
| | | | ||
|- | |- | ||
|CHAPTER 5 (PINEAL TUMOURS) | | | ||
====CHAPTER 5 (PINEAL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 792: | Line 799: | ||
|[[CNS5:Pineoblastoma|Pineoblastoma]] | |[[CNS5:Pineoblastoma|Pineoblastoma]] | ||
|Disease | |Disease | ||
|Fang Fang (trainee)+Katie Schieffer (mentor) | |||
|11/19/2025 | |||
|6/15/2026 | |||
|Pending | |||
| | | | ||
| | |LS | ||
| | | | ||
| | | | ||
| Line 823: | Line 830: | ||
| | | | ||
|- | |- | ||
|CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) | | | ||
====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 845: | Line 853: | ||
|[[CNS5:Schwannoma|Schwannoma]] | |[[CNS5:Schwannoma|Schwannoma]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5:Neurofibroma|Neurofibroma]] | |[[CNS5:Neurofibroma|Neurofibroma]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5:Perineurioma|Perineurioma]] | |[[CNS5:Perineurioma|Perineurioma]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
| Line 911: | Line 919: | ||
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
| Line 931: | Line 939: | ||
| | | | ||
|- | |- | ||
|CHAPTER 7 (MENINGIOMA) | | | ||
====CHAPTER 7 (MENINGIOMA)==== | |||
| | | | ||
---- | ---- | ||
| Line 962: | Line 971: | ||
| | | | ||
|- | |- | ||
|CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) | | | ||
====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 984: | Line 994: | ||
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] | ||
|Disease | |Disease | ||
| | |[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
| Line 1,050: | Line 1,060: | ||
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] | ||
|Disease | |Disease | ||
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
|[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 1,057: | Line 1,077: | ||
| | | | ||
| | | | ||
| | |||
| | |||
|- | |||
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]] | |||
|Disease | |||
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | |||
|- | |||
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] | |||
|Disease | |||
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,070: | Line 1,113: | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Chordoma|Chordoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,081: | Line 1,124: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 9 (MELANOCYTIC TUMOURS)==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,103: | Line 1,156: | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,114: | Line 1,167: | ||
| | | | ||
|- | |- | ||
|CHAPTER | | | ||
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,134: | Line 1,188: | ||
---- | ---- | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,145: | Line 1,199: | ||
| | | | ||
|- | |- | ||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
| | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] | ||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] | ||
|Disease | |Disease | ||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | |||
|- | |||
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] | |||
|Disease | |||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] | |||
|Disease | |||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] | |||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,205: | Line 1,264: | ||
| | | | ||
| | | | ||
|- | |||
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] | |||
|Disease | |||
|Jennie Thurston | |||
|7/2/2023 | |||
| | | | ||
|PENDING | |||
| | | | ||
|MS | |||
| | | | ||
|2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,220: | Line 1,287: | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] | ||
|Disease | |Disease | ||
| | |[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
|Disease | |Disease | ||
| | |[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] | ||
|Disease | |Disease | ||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |- | ||
|[[CNS5: | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] | |||
|Disease | |Disease | ||
| | |[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|N/A | |||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
| | | | ||
====CHAPTER 11 (GERM CELL TUMOURS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
|- | ---- | ||
|[[CNS5: | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |||
|[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] | |||
|Disease | |Disease | ||
| | | | ||
| Line 1,286: | Line 1,385: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,308: | Line 1,417: | ||
| | | | ||
|- | |- | ||
|[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] | |||
|Disease | |||
|[[CNS5: | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 1,330: | Line 1,428: | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,341: | Line 1,439: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] | ||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,372: | Line 1,461: | ||
| | | | ||
|- | |- | ||
|CHAPTER | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
| | |||
====CHAPTER 13 (METASTASES TO THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,392: | Line 1,493: | ||
---- | ---- | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,403: | Line 1,504: | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,414: | Line 1,515: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | |||
|- | |- | ||
| | |[[CNS5:Schwannomatosis|Schwannomatosis]] | ||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
| | | | ||
|- | |||
| | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | ||
|Disease | |||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
|N/A | |||
| | |N/A | ||
|N/A | |||
| | |N/A | ||
|N/A | |||
| | |N/A | ||
| | |||
| | |||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:Cowden_syndrome|Cowden syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,529: | Line 1,622: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,540: | Line 1,633: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,562: | Line 1,655: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,584: | Line 1,666: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5:Carney_complex|Carney complex]] | |||
|[[CNS5: | |||
|Disease | |Disease | ||
|[[ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| Line 1,607: | Line 1,677: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:DICER1_syndrome|DICER1 syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,617: | Line 1,688: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,628: | Line 1,699: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 1,652: | Line 1,723: | ||
| | | | ||
|- | |- | ||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5: | |[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,672: | Line 1,743: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:Fanconi_anaemia|Fanconi anaemia]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | | | ||
|- | |- | ||
|[[CNS5: | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] | ||
|Disease | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| Line 1,738: | Line 1,765: | ||
|N/A | |N/A | ||
|N/A | |N/A | ||
| | | | ||
|- | |- | ||
|} | |} | ||